Work

Bortezomib Followed by a Phase I Study of Bortezomib in Combination With High-Dose Melphalan as a Preparative Regimen for Hematopoietic Cell Transplants in Patients With Primary Refractory Multiple Myeloma or Plasma Cell Leukemia

Year: 2011

Type: article

Abstract: Preclinical and non-transplant clinical data indicates synergism between melphalan and bortezomib with enhanced melphalan-induced DNA damage via bortezomib-mediated down regulation of Fanconi anemia (FA)/BRCA DNA repair pathway. We designed a trial to examine the sequencing of high dose melphalan (100 mg/m2/day × 2 days), immediately followed by one dose of bortezomib (0.7, 1.0, or 1.3 mg/m2 on a phase I study design) and tandem autologous transplants. Thirty patients with primary refractory multiple myeloma or plasma cell leukemia were treated between 05/2005 and 02/2009.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2010.12.150